Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

January 17, 2024

Study Completion Date

October 31, 2025

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Avatrombopag Oral Tablet

Avatrombopag 20 mg given once daily (initial dose). Dosage adjustments were determined by the physician to maintain a platelet count between 50 x 10\^9 to 200 x 10\^9 as defined in the protocol and in accordance with overseas labeling.

Trial Locations (19)

441-8570

Sobi Site 105, Toyohashi

791-0295

Sobi Site 110, Tōon

820-8505

Sobi Site 118, Iizuka-shi

802-8555

Sobi Site 116, Kitakyushu

830-8543

Sobi Site 117, Kurume

500-8513

Sobi Site 114, Gifu

720-2121

Sobi Site 115, Fukuyama-shi

730-0052

Sobi Site 109, Hiroshima

650-0047

Sobi Site 108, Kobe

920-8650

Sobi Site 113, Kanazawa

028-3695

Sobi Site 101, Shiwa-gun

251-8550

Sobi Site 111, Fujisawa

862-8655

Sobi Site 119, Kumamoto

573-1191

Sobi Site 107, Hirakata

565-0871

Sobi Site 106, Suita

192-0032

Sobi Site 104, Hachiōji-shi

113-8603

Sobi Site 103, Bunkyō City

409-3898

Sobi Site 102, Chuo-shi

400-8506

Sobi Site 112, Kofu

All Listed Sponsors
lead

Sobi, Inc.

INDUSTRY